BiotechTube

DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thrombosis

Conditions

Thrombosis, Hip Replacement

Trial Timeline

May 1, 2006 → Jun 1, 2007

NCT ID
NCT00398216

About DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor

DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor is a phase 2 stage product being developed by Daiichi Sankyo for Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00398216. Target conditions include Thrombosis, Hip Replacement.

What happened to similar drugs?

8 of 20 similar drugs in Thrombosis were approved

Approved (8) Terminated (4) Active (11)
✅Alteplase "push" protocol + alteplase dwell armRocheApproved
✅Dalteparin sodium injection + WarfarinPfizerApproved
✅Low Molecular Weight Heparin (dalteparin)PfizerApproved
✅ApixabanPfizerApproved
✅ClexaneSanofiApproved
✅aspirin 75 mg/daySanofiApproved
✅enoxaparinSanofiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00398216Phase 2Completed

Competing Products

20 competing products in Thrombosis

See all competitors
ProductCompanyStageHype Score
CS1-Sodium ValproateCereno ScientificPhase 1
23
Edoxaban low dose + Edoxaban high doseDaiichi SankyoPhase 1
29
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarinDaiichi SankyoPhase 2
35
Rivaroxaban (Xarelto, BAY59-7939)Johnson & JohnsonPhase 2
35
Warfarin (Coumadin) + Rivaroxaban (Xarelto, BAY59-7939) + Placebo + Vitamin K (Konakion)Johnson & JohnsonPhase 1
29
Rivaroxaban (Xarelto, BAY59-7939) + Enoxaparin followed by VKAJohnson & JohnsonPhase 3
40
SHR2285 tablet + PlaceboJiangsu Hengrui MedicinePhase 1
29
SHR2285 + PlaceboJiangsu Hengrui MedicinePhase 1
29
Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、ticagrelor、placebo or SHR2285Jiangsu Hengrui MedicinePhase 1
29
Rosuvastatin (AZD4522) + PlaceboAstraZenecaPhase 3
32
MK-2060 + PlaceboMerckPhase 1
29
dabigatran etexilate + rivaroxabanMerckPhase 1
29
Alteplase "push" protocol + alteplase dwell armRocheApproved
35
Apixaban IR + Apixaban MR1 + Apixaban MR2 + Apixaban MR3PfizerPhase 1
29
Enoxaparin + warfarin + Placebo for apixaban + Placebo for enoxaparin + Placebo for warfarin + apixabanPfizerPhase 3
40
Apixaban + PlaceboPfizerPhase 3
40
90ug levonorgestrel / 20 ug ethinyl estradiol + Oral Contraceptives containing 20 ug of ethinyl estradiolPfizerPre-clinical
26
Fragmin (dalteparin sodium )PfizerPre-clinical
26
PD 0348292 + EnoxaparinPfizerPhase 2
35
Dalteparin + WarfarinPfizerPhase 2
35